Common Contracts
1 similar Master Licence Agreement contracts
MolMed and Takara Bio agreed on terminating the license agreement on TK therapy in Asian countriesMaster Licence Agreement • March 31st, 2016
Milan (Italy), March 31, 2016 – MolMed S.p.A. (MLM.MI) and Takara Bio Inc. (“Takara”) (OTCPK:TKBIF), today agreed on discontinuing their long lasting collaboration on TK (Zalmoxis®) by terminating all the related agreements, as Takara has not been able to produce the results planned by MolMed for the development and commercialization of the TK therapy in Asian countries.
